# Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant

> **NCT02684162** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 55 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
- Recurrent Acute Myeloid Leukemia
- Recurrent Myelodysplastic Syndrome

## Interventions

- **BIOLOGICAL:** Donor Lymphocytes
- **DRUG:** Guadecitabine
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02684162
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-22
- **Primary completion:** 2024-10-08
- **Final completion:** 2024-10-08
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02684162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02684162, "Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02684162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*